Skip to content
The Policy VaultThe Policy Vault

Ogsiveo — Blue Cross Blue Shield of Kansas

Desmoid tumors

Preferred products

  • sorafenib (generic)

Initial criteria

  • Target Agent(s) will be approved when ALL of the following are met (same general PA criteria as above) including verification of labeled or compendia-supported indication and prerequisite therapy as applicable.